Category Archives: Biochemistry

Biochemistry

Mynomx Pioneers the Personalization Science of Food Nutrition to Prevent and Fight Onset of COVID-19 – Business Wire

PALO ALTO, Calif.--(BUSINESS WIRE)--Mynomx Inc. (formerly Precision Wellness, Inc.), a Silicon Valley-based company at the intersection of next-generation AI analytics and the latest medical and nutrition science, today announced their personalized nutrition approach to boosting cardio and metabolic health for disease prevention and immune system support.

The Novel Coronavirus (COVID-19) has swept the world and struck those with underlying cardiometabolic syndrome: inflammation, hypertension, obesity, diabetes, and cardiovascular disorders, the hardest. The incidence and prevalence of people with cardiometabolic syndromes are on the rise, with over 40% of the US population suffering from one form of cardiovascular disease, posing the greatest burden as the nation's costliest chronic disease and number one killer.

It is clear a new approach to prevention is needed and one that involves proper nutritional interventions. Mynomx focuses on preventing the onset and progression of cardiovascular and metabolic disorders, using food as medicine, through an AI-driven personalized nutrition approach designed to each person's unique metabolism, biochemistry, health, and genetics.

"Expression of our genetic blueprint works hand-in-hand with our nutritional consumption to define our metabolism. The food that we eat directly affects the biochemical pathways that may result in a metabolic imbalance within every tissue and cell, including those of our immune system", explains Dr. Mehrdad Rezaee, Interventional Cardiologist at Cardiac and Vascular Care, a clinical scientist and a Mynomx co-founder.

The Mynomx personalized nutrition approach is predicated on AI health predictive and food recommendation engines designed from the ground up to improve balance across those cardio and metabolic pillars of health that prevent the onset of inflammation, hypertension, obesity, dyslipidemia, and diabetes.

According to Dr. Rezaee, "Achieving metabolic balance leads to an efficient metabolism which is associated with increased energy levels, optimal weight, and a bolstered immune system that can remove toxins, fight bacteria and viruses, and help in preventing the onset and severity of disease, as well as the recovery from injuries."

Unlike other food platforms that only score the quality of food without the knowledge of a person's true state of health, Mynomx's personalized nutrition platform connects food, nutrition, and health at the molecular level to provide precision nutrition food scoring and recommendations based on a person's unique biology and health.

Each person's unique health and biochemistry requires different nutrients, restrictions, and sensitivities that define their personalized dietary pattern. Mynomx combines this pattern with an individual's preference, to produce a curated list of foods ranked based on this precision nutrition score.

"We believe we can profoundly improve the health of our communities through actionable health insights and recommendations that use food-as-medicine personalized to bolster each person's metabolic response," explains Mynomx CEO Nazhin Zarghamee.

Mynomx AI applies this food scoring to whole foods, meals, packaged foods, restaurants, and recipes, to allow for healthy choices at the point of food shopping, meal selection, and meal planning decision making. Food retailers can use the Mynomx platform to build deeper personalization and engagement applications.

Mynomx's outcome-driven approach is predicated around nutritional guidelines and patterns designed to boost metabolic functioning and fight COVID-19. Government and self-insured organizations can use Mynomx predictive analytics to understand the at-risk population and deliver personalized nutrition programs to drive population health, ensuring the health of our communities.

Mynomx health predictions (previously Precision Wellness) have been validated with the highest levels of accuracy across 2.8M patient populations in conjunction with leading institutions such as Stanford Medicine [or University] & Broad Institute (a Harvard, MIT, Massachusetts General Hospital Collaborative). Reference Publication.

About Mynomx

Mynomx is a leading scientific food personalization company that offers organizations and individuals an advanced, integrative approach to managing their health through personalized health insights and nutritional intervention. The data-driven Mynomx analytic platform, powered by the latest in nutritional science at the molecular level, multi-omics, and next-generation AI, offers the means to manage health through "food as medicine," preventing disease and supporting healthy aging. In addition to serving individuals, our platform is ideal for insurance and self-insured organization, corporate wellness, testing, and diagnostic companies as well as food retailers who are seeking deeper personalization and engagement. To learn more, visit http://www.mynomx.com.

Go here to see the original:
Mynomx Pioneers the Personalization Science of Food Nutrition to Prevent and Fight Onset of COVID-19 - Business Wire

Biochemistry

NIH funding supports research on first therapeutic drug to regenerate heart tissue – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.May 29 2020

With funding from the National Institutes of Health, University of Arkansas researchers hope to develop the first therapeutic drug that can regenerate heart tissue. The lesion-seeking biological drug, released through stent placement, could treat coronary blockages and prevent heart failure.

Currently, there are no viable therapeutics available on the market that can promote regeneration of the heart to prevent myocardial infarction, or heart attack. All available medicines treat only symptoms to slow the onset of heart failure. The design of our biologics improves current methods of controlled release, because it takes advantage of specific biochemical events that occur during heart failure."

Josh Sakon, professor of biochemistry in the J. William Fulbright College of Arts and Sciences

Biologics, or biological drugs, are pharmaceutical products made from or containing components of living organisms. Used in biotechnology, biologics include a variety of products taken from humans, animals or microorganisms.

Sakon received $30,000 from the NIH - and a matching gift from the Commercialization Fund, a subset of the U of A Chancellor's Fund - to develop and commercialize sFGF1, a human "fibroblast growth factor" designed by Suresh Thallapuranam, professor of biochemistry. Fibroblast growth factors are cell-signaling proteins involved in a variety of processes critical to normal physiological development. Irregularities in the function of these proteins lead to a range of developmental defects.

Thallapuranam and Kartik Balachandran, associate professor of biomedical engineering, are part of Sakon's team focused on developing the drug. They are working on fusing sFGF1 with a different, collagen-binding protein released through stents, the thin mesh tubes that a heart surgeon inserts into arteries and blood vessels to relieve blockage and promote tissue healing. As Sakon mentioned, the advantage of their drug is that it functions in accordance with specific biochemical activity that occurs leading up to and during an adverse event.

In addition to funding drug development, the NIH award will help the researchers obtain intellectual property and pursue critical safety and feasibility assessments, including toxicity and biocompatibility testing in both lab and animal studies. Their results will be used to secure Small Business Technology Transfer funding for preclinical efficacy studies before seeking approval from the U.S. Food and Drug Administration. The NIH funding will also help the researchers identify a potential drug carrier.

The researchers' project is one of seven biomedical innovations funded by the NIH via XLerateHealth and its affiliate, the Southeast XLerator Network, which is led by the University of Kentucky. The award is part of the network's Ideas to Products program that supports researchers with competitive proof-of-concept funding that will help accelerate healthcare technologies for commercialization.

With 24 academic institutions, the Southeast XLerator Network was created to support the commercialization of promising life science and healthcare innovation in several southeastern states and Puerto Rico. Its program goal is to broaden the geographic distribution of NIH funding and to help accelerate early-stage biomedical technology from laboratory to market, with an emphasis on supporting geographically underserved areas in healthcare.

According to the American Heart Association, more than 600,000 Americans experience a new myocardial infarction each year, with 275,000 deaths attributable to heart failure. About one in four patients who survive an initial heart attack develop heart failure within four years of the initial first heart attack. Rapid diagnosis and intervention after a coronary blockage can significantly improve chances of patient survival.

Original post:
NIH funding supports research on first therapeutic drug to regenerate heart tissue - News-Medical.Net

Biochemistry

2020 Current trends in Automatic Veterinary Biochemistry Analyzer Market Share, Growth, Demand, Trends, Region Wise Analysis of Top Players and…

Automatic Veterinary Biochemistry Analyzer Market 2020: Latest Analysis

Chicago, United States: The global Automatic Veterinary Biochemistry Analyzer Market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. Report Hive Researchs latest publication, titled global Automatic Veterinary Biochemistry Analyzer market, offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Automatic Veterinary Biochemistry Analyzer market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. The Automatic Veterinary Biochemistry Analyzer market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

This study covers following key players: Biochemical Systems InternationalBPC BioSedCarolina Liquid ChemistriesAbaxis EuropeAMS AllianceRandox LaboratoriesRayto Life and Analytical SciencesScil Animal CareCrony InstrumentsDiaSys Diagnostic SystemsEurolyser DiagnosticaGesan ProductionHeskaIdexx LaboratoriesLITEON IT CorporationShenzhen Icubio Biomedical TechnologyURIT Medical Electronic

To know How COVID-19 Pandemic Will Impact This Market/Industry | Get the Sample of this Report with Detail TOC and List of [emailprotected]

NOTE: Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Automatic Veterinary Biochemistry Analyzer Market which would mention How the Covid-19 is Affecting the Automatic Veterinary Biochemistry Analyzer Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Automatic Veterinary Biochemistry Analyzer Players to Combat Covid-19 Impact.

The research report covers the trends that are currently implemented by the major manufacturers in the Automatic Veterinary Biochemistry Analyzer market including adoption of new technology, government investments on R&D, shifting in perspective towards sustainability, and others. Additionally, the researchers have also provided the figures necessary to understand the manufacturer and its contribution to both regional and global market:

The Essential Content Covered in the Global Automatic Veterinary Biochemistry Analyzer Market Report :

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Market segment by Type, the product can be split into:

Bench-Top Veterinary Biochemistry AnalyzerPortable Veterinary Biochemistry Analyzer

Market segment by Application, split into:

Pet HospitalVeterinary Station

The report answers important questions that companies may have when operating in the global Automatic Veterinary Biochemistry Analyzer market. Some of the questions are given below:

What will be the size of the global Automatic Veterinary Biochemistry Analyzer market in 2025? What is the current CAGR of the global Automatic Veterinary Biochemistry Analyzer market? Which product is expected to show the highest market growth? Which application is projected to gain a lions share of the global Automatic Veterinary Biochemistry Analyzer market? Which region is foretold to create the most number of opportunities in the global Automatic Veterinary Biochemistry Analyzer market? Will there be any changes in market competition during the forecast period? Which are the top players currently operating in the global Automatic Veterinary Biochemistry Analyzer market? How will the market situation change in the coming years? What are the common business tactics adopted by players? What is the growth outlook of the global Automatic Veterinary Biochemistry Analyzer market?

The scope of the Report:

The report segments the global Automatic Veterinary Biochemistry Analyzer market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Automatic Veterinary Biochemistry Analyzer market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Get Customized PDF template of this report: https://www.reporthive.com/request_customization/2311706

There are 15 Chapters to display the Automatic Veterinary Biochemistry Analyzer Market Research.

Chapter 1, to describe Definition, Specifications and Classification of Automatic Veterinary Biochemistry Analyzer , Applications of Automatic Veterinary Biochemistry Analyzer , Market Segment by Regions;

Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Automatic Veterinary Biochemistry Analyzer , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis;

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc., Automatic Veterinary Biochemistry Analyzer Segment Market Analysis;

Chapter 7 and 8, to analyze the Automatic Veterinary Biochemistry Analyzer Segment Market Analysis (by Application) Major Manufacturers Analysis of Automatic Veterinary Biochemistry Analyzer;

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyze the Consumers Analysis of Automatic Veterinary Biochemistry Analyzer;

Chapter 12, to describe Automatic Veterinary Biochemistry Analyzer Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Automatic Veterinary Biochemistry Analyzer sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Speak to Research Analyst: +1-312-604-7084

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

Continued here:
2020 Current trends in Automatic Veterinary Biochemistry Analyzer Market Share, Growth, Demand, Trends, Region Wise Analysis of Top Players and...

Biochemistry

The global veterinary point-of-care diagnostics market size is projected to reach USD 2.4 billion by 2025 from USD 1.4 billion in 2019, at a CAGR of…

NEW YORK, May 29, 2020 /PRNewswire/ -- The global veterinary point-of-care diagnostics market is projected to grow at a CAGR of 8.9% during the forecast year.

Read the full report: https://www.reportlinker.com/p05902706/?utm_source=PRN

The global veterinary point-of-care diagnostics market size is projected to reach USD 2.4 billion by 2025 from USD 1.4 billion in 2019, at a CAGR of 8.9%. The increasing prevalence of zoonotic diseases among companion and livestock animals and the growing need for rapid disease detection are the major factors driving the growth of this market. However, the high cost of veterinary imaging instruments is expected to restrain market growth to a certain extent.

The consumables segment dominates the veterinary point-of-care diagnostics market." Based on product, the veterinary point-of-care diagnostics market is segmented into consumables and instruments. Consumables accounted for the largest market share in 2018. The large share of the consumables segment can be attributed to the increasing demand for the rapid detection of diseases, the growing prevalence of animal zoonotic diseases, and growth in the companion animal population worldwide. This segment is also expected to grow at the highest CAGR during the forecast period.

By technology, the clinical biochemistry segment accounted for the largest share of the veterinary point-of-care diagnostics market in 2018.On the basis of technology, the veterinary point-of-care diagnostic kits & analyzers market has been segmented into immunodiagnostics, clinical biochemistry, hematology, urinalysis, molecular diagnostics, and other technologies.The clinical biochemistry segment accounted for the largest share of the veterinary point-of-care diagnostic kits & analyzers market in 2018.

The higher preference for advanced clinical diagnostic products by veterinarians and pet owners and the wide applications of this technology are contributing to the large share of this market.

The Asia Pacific market to witness the highest growth during the forecast period.The Asia Pacific market is expected to witness the highest growth during the forecast period, primarily due to the rapidly increasing animal population, growing adoption of veterinary diagnostic products, and rising demand for animal-derived food products.

Breakdown of primary participants is as mentioned below: By Company Type: Tier 1: 35%, Tier 2: 40%, and Tier 3: 25% By Designation: C-level: 35%, Director-level: 25%, and Others: 40% By Region: North America: 35%, Europe: 30%, Asia Pacific: 15%, Middle East and Africa: 10%, and Latin America: 10%

Prominent players in the veterinary point-of-care diagnostics market are Zoetis, Inc. (US), IDEXX Laboratories, Inc. (US), Heska Corporation (US), Virbac (France), Thermo Fisher Scientific, Inc. (US), Eurolyser Diagnostica GmbH (Austria), Woodley Equipment Company (UK), Randox Laboratories Ltd. (UK), AniPOC, Ltd. (UK), Carestream Health, Inc. (a part of ONEX Corporation) (Canada), NeuroLogica Corporation (a part of Samsung Electronics Co. Ltd.) (South Korea), and FUJIFILM SonoSite (a part of FUJIFILM Holdings Corporation) (Japan).

Research Coverage:The report analyzes the veterinary point-of-care diagnostics market and aims at estimating the market size and future growth potential of this market based on various segments, such as product, technology, application, animal type, end user, and region.It also covers competitive leadership mapping, which helps in analyzing the position of key market players as visionary leaders, innovators, dynamic players, and emerging players.

The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the ReportThe report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them to garner a greater market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers: Market Penetration: Comprehensive information on product portfolios offered by the top players in the global veterinary point-of-care diagnostics market. The report analyzes this market by product, technology, application, animal type, end user, and region. Product Enhancement/Innovation: Detailed insights on upcoming trends and launches in the global veterinary point-of-care diagnostics industry Market Development: Comprehensive information on the lucrative emerging markets by product, application, animal, end user, technology, and region Market Diversification: Exhaustive information about new testing services, growing geographies, recent developments, and investments in the global veterinary point-of-care diagnostics industry Competitive Assessment: In-depth assessment of market shares, growth strategies, service offerings, and capabilities of leading players in the global veterinary point-of-care diagnostics market

Read the full report: https://www.reportlinker.com/p05902706/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read more:
The global veterinary point-of-care diagnostics market size is projected to reach USD 2.4 billion by 2025 from USD 1.4 billion in 2019, at a CAGR of...

Biochemistry

Scientists discover two anti-inflammatory drugs that inhibit COVID-19 infection – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.May 27 2020

Since the outbreak of the COVID-19 pandemic and its rapid spread, the scientific community has been working on developing an effective treatment for the virus responsible for the disease.

Finding drugs that can inhibit the infection caused by SARS-CoV-2 is an essential step to finding the vaccine that can definitively bring the spread of the virus to an end.

In this regard, the URV's Cheminformatics and Nutrition research group has carried out a computational screening to predict whether there is a medicine authorised for treating another pathology that can inhibit the main protease of the virus (M-pro).

This is key to the whole process because this enzyme plays an essential role in the replication of the virus.

The study demonstrates that a human and a veterinary anti-inflammatory drug - Carprofen and Celecoxib - inhibit a key enzyme in the replication and transcription of the virus responsible for COVID-19.

The aim of the study was to use computer techniques to analyze whether 6,466 drugs authorized by various drug agencies for both human and veterinary use could be used to inhibit the M-pro enzyme.

This enzyme is a protease that is responsible for cutting two polypeptides (generated by the virus itself) and generating a number of proteins that are essential for the reproduction of the virus.

Some of the trials coordinated by the WHO against the COVID-19 pandemic also aim to inhibit M-pro using two antiretrovirals such as Lopinavir and Ritonavir (drugs initially designed to treat HIV).

As a result of the study conducted at the URV, it has been predicted that 7 of these 6,466 drugs may inhibit M-pro.

The results have been shared with the international initiative COVID Moonshot which has selected 2 of these 7 compounds (i.e., Carprofen and Celecoxib) in order to test their ability to inhibit M-pro in vitro.

The results obtained show that at a concentration of 50 M of Celecoxib or Carprofen, the inhibition of the in vitro activity of M-pro is 11.90 and 4.0%, respectively. Therefore, both molecules could be used as a starting point for further lead optimization to obtain even more potent derivatives.

The study by the Cheminformatics and Nutrition research group from the Biochemistry and Biotechnology Department of the URV has been led by Drs. Gerard Pujadas and Santi Garcia-Vallv with the collaboration of Drs. Aleix Gimeno, Mara Jos Ojeda-Montes and Adri Cereto-Massagu, the PhD students Guillem Macip and Bryan Saldivar-Espinoza and student Jlia Mestres-Truyol (double degree student in Biotechnology and in Biochemistry and Molecular Biology at the URV).

It has been published by the International Journal of Molecular Sciences (IJMS) and is the first to be published worldwide on drug repositioning as inhibitors of SARS-CoV-2 M-pro where computational predictions are experimentally corroborated.

The remaining 5 molecules are expected to be selected soon by COVID Moonshot so that their bioactivity can be tested as well.

Source:

Journal reference:

Gimeno A. et al. (2020) Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. International Journal of Molecular Sciences. doi.org/10.3390/ijms21113793.

See more here:
Scientists discover two anti-inflammatory drugs that inhibit COVID-19 infection - News-Medical.Net

Biochemistry

Couple on the coronavirus front lines – UCI News

Naptime is over.

Ilhem Messaoudi Powers, associate professor of molecular biology & biochemistry at UCI, is enjoying a rare weekend at home with her husband, Dr. Michael Powers, when they hear the rustling of their two young children.

He bounds up the stairs to retrieve Owen, 3, and Olivia, 6 months, from a Saturday afternoon slumber. Soon the living room is full of the joyous noises of a toddler and an infant.

When theyre not wearing their mommy and daddy hats, Ilhem and Michael Powers are exploring and immersing themselves in an entirely different world: the COVID-19 pandemic.

A virologist and immunologist, Ilhem Powers leads a team of researchers whove launched a surveillance study of UCI Health workers to determine how many have antibodies against the coronavirus.

Michael Powers is a pulmonologist who works as a critical care doctor at the Naval Medical Center San Diego, caring for patients with COVID-19, as well as others.

Because of his unpredictable schedule, he often stays for days at an apartment in San Diego while his wife, with the assistance of a part-time nanny, juggles kids and career from the couples on-campus home and her laboratory.

Mike and I have been through a lot together, she says. Weve really learned to focus on the now.

Indeed, her husband was just two weeks into medical school at New Orleans Tulane University when Hurricane Katrina hit in late August of 2005. Ilhem Powers had accepted a job at the school as an assistant professor and was getting ready to relocate from their previous home in Portland, Oregon.

The New Orleans duplex that the couple had renovated with most of their savings wound up under 8 feet of water. It took them more than a year to recover.

One of the biggest lessons Ive learned in life is to focus on the things you have some control over, Michael Powers says. You just have to let go of the rest.

Surveillance study

Ilhem Powers lab cohort have pivoted from their usual work to conduct COVID-19 research as members of UCIs Institute for Immunology and Center for Virus Research.

Their surveillance study, funded by a $60,000 UCI grant and expected to last a year, will repeatedly examine 300 healthcare providers. The collection of samples has already begun.

We want to know how many of them may have already been exposed [to COVID-19] and didnt know about it and how many of them potentially have immunity, Ilhem Powers says. Well take blood samples and nose swabs to measure antibodies and T cell responses, which kill infected cells, as well as potential asymptomatic shedding. Its a multipronged approach.

Arriving at UCI in January 2017 after serving as a researcher and assistant professor at UC Riversides School of Medicine, she has years of experience studying how the human immune system interacts with emerging viral diseases such as Ebola, Chikungunya, Zika and monkeypox.

For some viruses, Ilhem Powers explains, antibodies are sufficient [to kill them]. For others, you need more of a T cell response. We dont yet know enough about this novel coronavirus.

More community surveillance needs to be done, she says: How many people have potential COVID-19 antibodies? We also need to look at the immune response in patients those currently in hospitals and then determine the difference between the immune response of those who end up in the ICU versus those who end up being sent home.

Health scare

Michael Powers, who began his residency at the Naval Medical Center San Diego in 2010, says the COVID-19 pandemic has forced him and other doctors to live with a lot of uncertainty.

But he has a stoic air about him despite his relatively new role of treating patients with a little-understood disease. Perhaps experiencing a serious lung-related health scare himself contributes to his even-keeled nature.

During his wifes last year at UC Riverside, Michael Powers went on an outreach mission to Ghana. Shortly after returning home, he developed MRSA in his lungs and had to undergo thoracic surgery. He spent 10 days in the hospital and 30 days in convalescence.

It was a pulmonologists worst nightmare, Ilhem Powers says. It was really scary.

So is COVID-19, her husband says: I think a lot of people have a very romanticized notion of what ICU-level care is and being on a ventilator. The movies definitely dont do it justice.

When people go on ventilators, its not at all uncommon for them to be on them for two weeks or more. Its not a pleasant thing to have a giant plastic tube down your throat and a machine telling you when to breathe.

Enjoying the little moments

Michael Powers says he takes extreme precautions at work and elsewhere in San Diego before driving up to Irvine to spend time with his wife and children.

People ask me all the time, Isnt he worried? Ilhem Powers says. They ask, Shouldnt he just stay in his apartment and not come up here and pose a health risk to you and your kids? And we just say we understand and accept the risk.

She and her colleagues get tested regularly for COVID-19 using equipment in their lab.

Having already weathered a lot of adversity, the couple believe theyre uniquely equipped to cope with COVID-19.

What we both do for a living, and our past experience dealing with crises, has put us in this perfect position to deal with this pandemic, he says.

For many people, she adds, this is the first time that things outside their control have completely dominated their life.

Often, the two will sit down and go over COVID-19 research papers together and compare notes, discussing where the pandemic is headed, possible therapies and longer term potential vaccines.

But they make sure that when theyre together, they shower most of their attention on Owen and Olivia.

When hes home, Ilhem Powers says of her husband, its family time. For us, its all about enjoying the little moments.

Read the original here:
Couple on the coronavirus front lines - UCI News

Biochemistry

According to Latest Report on Dicyandiamide (CAS 461-58-5) Market to Grow with an Impressive CAGR Shandong Efirm Biochemistry, Ningxia Baoma Chemical…

Dicyandiamide (CAS 461-58-5) Market Research Report 2020 With COVID-19 Analysis

The global market report is a systematic research of the global Dicyandiamide (CAS 461-58-5) Market portraying the current state of affairs in the market. Further, it offers an estimation of the market measure as far as esteem and in volume and discusses the key fragments and the topographical subdivisions of the market for Dicyandiamide (CAS 461-58-5) advertise in subtle elements.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/14729

Key Competitors of the Global Dicyandiamide (CAS 461-58-5) Market are: , AlzChem, NCI, Denka, Jiafeng Chemical, Ningxia Sunnyfield Chemical, Darong Group, Gulang Xinmiao, Yinglite Chemical, Beilite Chemical, Shandong Efirm Biochemistry, Ningxia Baoma Chemical

The fundamental purpose of Dicyandiamide (CAS 461-58-5)Market report is to provide a correct and strategic analysis of the Dicyandiamide (CAS 461-58-5) industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

It gives top to bottom instructive information on the advancement patterns and the approaches and controls, concerning Dicyandiamide (CAS 461-58-5) showcase, actualized in every one of the topographical sections. The dominating utilizations of this market have additionally been talked about finally in this exploration consider.

Major Product Types covered are: , Calcium Cyanamide Granular, Calcium Cyanamide Powder

Major Applications of Dicyandiamide (CAS 461-58-5) covered are: , Fertilizer Industry, Pesticide Industry, Others

To get this report at a profitable rate.: https://reportsinsights.com/discount/14729

What are the affecting elements that are made reference to in the report?

Market Scenario:The report further highlights the development trends in the global Dicyandiamide (CAS 461-58-5) market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Key Market Highlights:The Dicyandiamide (CAS 461-58-5) report gives a top to bottom examination on a portion of the key elements, involving income, cost, limit, limit usage rate, creation, generation rate, utilization, import/send out, supply/request, net, piece of the pie, CAGR, and gross edge. Furthermore, the report shows a far reaching investigation of the market development factors and their most recent patterns, alongside important market fragments and sub-portions.

Analytical Tools:The Global Dicyandiamide (CAS 461-58-5) Market report incorporates the decisively examined and assessed information of the significant market members and their market scope utilizing various investigative devices. The diagnostic apparatuses incorporate Porters five powers examination, SWOT investigation, achievability study, and venture return investigation, which have been utilized to consider the development of the key players working in the market.

The main points which are answered and covered in this Report are-

What will be the total Dicyandiamide (CAS 461-58-5) Market in the coming years till 2026?What will be the key factors which will be overall affecting the industry?What are the various challenges addressed?Which are the major companies included?

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Dicyandiamide-CAS-461-58-5-Market-14729

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:info@reportsinsights.com

Sales:sales@reportsinsights.com

Originally posted here:
According to Latest Report on Dicyandiamide (CAS 461-58-5) Market to Grow with an Impressive CAGR Shandong Efirm Biochemistry, Ningxia Baoma Chemical...

Biochemistry

Chitosan Market Size Worth $28.93 Billion by 2027 | CAGR 24.7%: Grand View Research, Inc. – PRNewswire

SAN FRANCISCO, May 25, 2020 /PRNewswire/ -- The global chitosan marketsize is projected to reach USD 28.93 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a revenue-based CAGR of 24.7% during the forecast period. Increasing consumption of bio-derived products in water treatment, cosmetics, food and beverage, and pharmaceutical industries is likely to derive the growth.

Key suggestions from the report:

Read 102 page research report with ToC on "Chitosan Market Size, Share & Trends Analysis Report By Application (Pharmaceutical & Biomedical, Water Treatment, Cosmetics, Food & Beverage), By Region (APAC, North America, Europe, MEA), And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/global-chitosan-market

Chitosan is marketed under various grades, such as industrial, pharmaceutical, and food depending upon the purity of the product. In the pharmaceutical industry, it is used as diluents for tablets, a binder in wet granulations, dis-integrant, drug carrier, and absorption enhancer. In addition, chitosan and its derivatives can easily penetrate the plasmatic membrane of microorganisms and kill bacteria, fungi, and other parasites. Hence, is used for treating infections in orthopedic, neurological, gynecological, and cardiovascular surgical procedures.

North America is expected to emerge as one of the major markets for chitosan during the forecasted period, registering a CAGR of 19.2% in terms of volume, between 2020 to 2027. The region has experienced a growing demand for chitosan products owing to increasing biobased industries. Manufacturers are heavily investing in R&D activities to develop the pure grade of chitosan. However, high production cost owing to the irregular supply of the raw material is anticipated to hamper market growth over the forecast period.

The market is highly fragmented in nature owing to the presence of a large number of small-scale players, especially in countries including Japan, China, Thailand, and South Korea. These countries have favorable government regulations to promote growth of their fishery industry. Hence, several companies such as Qingdao Yunzhou Biochemistry Co., Kyowa Technos Co., Ltd., Dainichiseika Color & Chemicals Mfg. Co. Ltd., and KIMICA Corporation have manufacturing as well as distribution channels present in the region.

Grand View Research has segmented the global chitosan market on the basis of application and region:

Find more research reports on Renewable Chemicals Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected] Web: https://www.grandviewresearch.com Follow Us: LinkedIn | Twitter

SOURCE Grand View Research, Inc.

Link:
Chitosan Market Size Worth $28.93 Billion by 2027 | CAGR 24.7%: Grand View Research, Inc. - PRNewswire

Biochemistry

Research Roundup: Emerging Viral Diseases and More – BioSpace

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

More Worries About Emerging Viral Diseases

If the current COVID-19 pandemic is teaching the world anything, its that viral diseases can be extremely dangerous and disruptive. Researchers with the University of Colorado Anschutz Medical Campus released a new study calling attention to the emergence of mosquito-borne viral outbreaks in West Africa, including dengue (DNV), chikungunya (CHIKV) and Zika (ZIKV) viruses. They published their research in Acta Tropica.

The study reviewed 50 years of literature on arboviruses in West Africa. The goal was to define evidence of DENV, ZIKV and CHIKV and the distribution of their Aedes mosquito vectors in the region. They found strong evidence that transmission of these diseases is occurring in urban areas of West Africa, which is distinct from the rural transmission of yellow fever virus that has been historically present in the region. They found evidence that the epidemiology of arboviral disease in West Africa has shifted and that rapid urbanization and climate change could increase risk of outbreaks in the future.

Large arboviral outbreaks will occur around the world, said Elizabeth Carlton, assistant professor of environmental and occupational health at the Colorado School of Public Health and co-author of the study. Building awareness and surveillance capacity before the outbreaks occur can help detect outbreaks early and enable prompt and effective response to reduce health impacts.

Research lead Andrea Buchwald, a postdoctoral fellow, said, Emerging viruses are at the forefront of everyones attention due to the COVID-19 pandemic. It has underscored the importance of preparing for and preventing large viral outbreaks that can have massive public health and economic consequences. We hope our research will prompt the development of early warning systems and adoption of control measures to prevent infectious outbreaks in West Africa. This will greatly impact the spread and severity of future outbreaks.

Vaccine Design Leveraging Artificial Proteins

Investigators at Ecole Polytechnique Federale de Lausanne in France developed a computational approach to create artificial proteins, which they believe could be used to create safer and more effective vaccines. They note that when vaccines dont work, theres a tendency to think its because the antibodies produced arent protective, but usually its because the immune system is making the wrong type of antibodies. The new method was able to design artificial proteins that could precisely instruct the bodys immune system which antibodies to produce.

New Genetic Link for NASH Identified

Non-alcoholic steatohepatitis is a fatty liver disease similar to cirrhosis of the liver but in people who drink little or no alcohol. Researchers at German Diabetes Center, German Institute of Human Nutrition Potsdam-Rehbrucke (DlfE), and Helmholtz Zentrum Munchen, discovered new genes that play a role in fatty liver disease. The genes are IRGM, Ifgga2 and Ifgga4. They are responsible for the production of regulatory proteins of the family of immunity-related GTPases that counteract fat accumulation in the liver. A genetic variation causes formation of fewer of these proteins.

University of Waterloo researchers studying the 3D structure of the COVID-19 protein believe a specific class of diabetes drugs could potentially be used to treat COVID-19. The study has not yet been peer-reviewed, but they found evidence that dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors) could bind to the protein. They are continuing research and hope to scale up to clinical trials. Common DPP4 inhibitors include AstraZenecas Onglyza (saxagliptin), Mercks Januvia (sitagliptin), Takedas Nesina (alogliptin) and Boehringer Ingelheims Tradjenta (linagliptin).

How Triglyceride is Made

Triglycerides are a type of dietary fat that are associated with increased risk of heart disease, diabetes, obesity and fatty liver disease. Researchers at Baylor College of Medicine identified a 3D structure and mode of action of an enzyme, acylglycerol O-acyltransferase-1 (DGAT1) that synthesizes triglycerides. It is also required for human dietary fat absorption and storage. DGAT1 is a known target for treating diabetes and metabolic diseases, so understanding the mechanism of action may lead to better interventions. The research was published in the journal Nature.

DGAT1 is a particularly interesting enzyme because it synthesizes triglycerides, which are the main component of hard fat, the type of fat usually found in the belly or midsection in our body, said co-corresponding author Ming Zhou, Ruth McLean Bowman Bowers Professor in Biochemistry in the Department of Biochemistry and Molecular Biology at Baylor. Triglycerides also are part of the particles that transport cholesterol high-density lipoproteins (HDL, or good cholesterol), and low-density and very-low-density lipoproteins (LDL and VLDLD, or bad cholesterols). Learning to regulate this enzyme can help regulate fat synthesis and potentially manage related conditions.

Accumulated Neuron Damage as We Age

Researchers at Massachusetts Institute of Technology (MIT) identified an enzyme called HDAC1 that is critical for repairing age-related DNA damage in genes associated with memory and cognition. In Alzheimers patients, as well as in normally aging adults, HDAC1 is often found in lower amounts. Their research suggests that restoring the enzyme could have benefits for both groups. The research was published in the journal Nature Communications.

It seems that HDAX1 is really an anti-aging molecule, said Li-Huei Tsai, director of MITs Picower Institute for Learning and Memory, and senior author of the research. I think this is a very broadly applicable basic biology finding, because nearly all of the human neurodegenerative diseases only happen during aging. I would speculate that activating HDAC1 is beneficial in many conditions.

In 2013, the same group published two papers linking HDAC1 to DNA repair in brain cells. The new research studied what happens when HDAC1-mediated repair didnt happen. They worked with mice engineered to not produce HDAC1 in neurons and another type of brain cell, astrocytes. At first there was no noticeable difference in DNA damage levels or behavior, but as the mice aged, DNA damage began to accumulate in the HDAC1-deficient mice and lost some of their brain plasticity and problems in memory and spatial navigation. The loss of HDAC1 was associated with a specific type of DNA damage called 8-oxo-guanine lesions.

Link:
Research Roundup: Emerging Viral Diseases and More - BioSpace

Biochemistry

What scientists are learning to try to be ready for what’s after COVID-19 – Minneapolis Star Tribune

CHICAGO More than a decade ago, a center was founded at Northwestern University as a rapid-response operation against infectious disease. But its work was sporadic a boom when epidemics hit, a bust when they were under control.

Now, researchers with the Center for Structural Genomics of Infectious Diseases are rushing to find a treatment for COVID-19, making up for lost time. And they hope theyll be ready for whatever comes next.

I think were making substantial strides, said Karla Satchell, director of the center who is a professor of microbiology-immunology at Northwesterns Feinberg School of Medicine. Our hope is that we can do something in time to help this round of the pandemic. But at the very least, we can do enough that this wont happen again.

Andy Mesecar, an expert in biochemistry and gene therapy, is on the front lines of that fight. He has been working seven-day weeks, racing to find a drug for COVID-19, teaching at Purdue University and submitting daily reports to the National Institutes of Health.

His lab is one of the leading centers studying coronaviruses, and he and his team have dedicated nearly two decades to the research. With a background in biochemistry and structural biology, Mesecar started out studying enzymes that could fight cancer. He got into infectious diseases after the anthrax attacks in the weeks after 9/11. Then, he pivoted to studying enzymes that could be used against SARS when it surfaced in November 2002. My training in structural biology allows me to work on any diseases that go around, he said. I can apply it to any disease and do so rapidly.

The bulk of coronavirus research began during the SARS epidemic and through the MERS outbreak less than 10 years later. Hardly anything was known about coronaviruses at the time, Satchell said, so researchers sprinted to learn its biochemistry.

During the basic science phase of drug discovery, researchers identify the genetic sequence of a protein or enzyme that is essential to the virus replication, then look for a compound that blocks it, called the inhibitor. The compounds are developed into a drug that not only lasts long enough in the body to kill the virus but is also nontoxic. Only then can it move to animal trials.

Mesecar spent years studying SARS, then MERS. But as the outbreaks waned, funding dried up. To continue their work, his team scoured for small amounts of funding, but even three years ago, they didnt have enough to support a single person fully. Then the center at Northwestern stepped in.

But the lull in funding had already done its damage, Satchell said. No clinical trials of the compounds had been done by the time the pandemic hit. Nothing ever got out of the laboratory (for SARS), she said. Theres no treatment for COVID-19 that is specific to this virus and this infection, and the research tracking it really seems like it just ended.

When MERS emerged in 2012, Mesecars team switched to this new coronavirus, publishing papers that shared their discovery of compounds that worked against it. He and his team were among the first to predict that the next coronavirus outbreak would come from bats, the suspected origin of COVID-19. Everything we did was to predict the next outbreak, he said. What we wanted to do was to have compounds that could rapidly move toward the particular coronavirus strain that emerged.

Satchell, Mesecar and others point to earlier failings as a cautionary tale. Mesecar said researchers should study the effects of certain compounds on animals so they could be more quickly developed when new viruses appear. This was the key to remdesivir reaching patients now. Were not as far behind as we could be because of the love and ingenuity of scientists who want to pursue and learn about it, he said.

The coronavirus field is undergoing a rapid change. Satchell said, more funding will be needed and more scientists will need to remain in the field. Shes seen this effect with tuberculosis, anthrax attacks and SARS, and she believes this pandemic will yield similar results. In order to be prepared for the next public health threat, she said, scientists will need to break new ground.

You can make a lot of movement fast, based on what you know, Satchell said. But at some point, you hit a wall where you have to discover new things.

Original post:
What scientists are learning to try to be ready for what's after COVID-19 - Minneapolis Star Tribune